Kadcyla (ado-trastuzumab emtansine) for Injection, for Intravenous Use 

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) April 2016 BOXED WARNING Embryo-Fetal Toxicity: Exposure to KADCYLA during pregnancy can result in embryo-fetal harm. Advise...
Source: Drugs.com - Labeling Changes - Category: Drugs & Pharmacology Source Type: alerts